CDT Equity Amends ELOC & Convertible Note with Unfavorable Terms

summarizeSummary

CDT Equity Inc. amended its Equity Line of Credit and a convertible note, agreeing to a $510,000 purchase and diverting 10% of future capital raises to debt repayment under terms effective only until May 31, 2026.

check_boxKey Events · Financing and Capital Events · CDT

• Equity Line of Credit Amended

  The company amended its directed stock purchase agreement, setting a gross purchase price of $510,000 for regular purchases and extending an 'Adjustment Period' that could result in additional dilutive share issuances if the stock price drops after the investor's purchase.

• Convertible Note Amended

  An amendment to a Senior Secured Convertible Promissory Note now requires 10% of all future debt or equity financing proceeds, including from the ELOC, to be used for repayment of the note.

• Short-Term Effectiveness

  Both amendments are only effective through May 31, 2026, indicating a very short-term financial arrangement.

• Going Concern Context

  These highly dilutive and unfavorable financing terms come after the company's recent 10-K filing disclosed substantial doubt about its ability to continue as a going concern.

auto_awesomeAnalysis · CDT · Life Sciences

CDT Equity Inc. has amended its Equity Line of Credit (ELOC) and a Senior Secured Convertible Promissory Note. The ELOC amendment sets a gross purchase price of $510,000 for regular purchases and extends an 'Adjustment Period' which could lead to further dilution if the stock price declines after the investor's purchase. The Convertible Note amendment mandates that 10% of all future debt or equity financing proceeds, including from the ELOC, must be used to repay the note. These amendments, effective only until May 31, 2026, represent a short-term and costly capital raise for a company that recently disclosed substantial doubt about its ability to continue as a going concern. The terms are highly unfavorable, diverting much-needed capital to debt repayment and exposing shareholders to significant potential dilution.